<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1985">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05601856</url>
  </required_header>
  <id_info>
    <org_study_id>HSR220333</org_study_id>
    <nct_id>NCT05601856</nct_id>
  </id_info>
  <brief_title>Gut Microbiome and Blood Indices in Patients With AD and Their Spousal Caregivers</brief_title>
  <official_title>Gut Microbiome and Blood Indices in Patients With AD and Their Spousal Caregivers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Spousal caregivers of Alzheimer's Dementia (AD) patients have an elevated risk of developing&#xD;
      AD in the future. Past studies have shown the presence of serum indicators correlated with&#xD;
      gut biome dysfunction in AD patients. We hypothesize that the same gut biome dysfunction may&#xD;
      be present in spousal caregivers of AD patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with Alzheimer's disease (AD) have gut dysbiosis. Short-chain fatty acids (SCFAs)&#xD;
      are products of the gut microbiome. Among them, Acetate and valeric acid were positively&#xD;
      correlated with the Aβ plaque load detected by amyloid PET in participants with or without&#xD;
      AD. However, the levels of SCFAs in the blood of patients with AD have not been defined.&#xD;
      Also, the usefulness of indices of inflammation and neuropathology in the blood as biomarkers&#xD;
      for cognitive impairment in patients with AD is elusive. Importantly, spousal caregivers of&#xD;
      patients with dementia have a higher risk of developing dementia later in life than those&#xD;
      whose spouses do not have dementia. The spousal caregivers have an accelerated cognitive&#xD;
      decline. The mechanisms for these phenomena are not known. We hypothesize that spousal&#xD;
      caregivers of patients with AD have gut microbiome and levels of blood SCFAs similar to those&#xD;
      of patients with AD, that these spouses have increased inflammatory cytokines and indices of&#xD;
      AD-like neuropathology in the blood, and that there is a correlation between the cognition&#xD;
      and various indices in the blood among patients with AD, their spouses, and age-matched&#xD;
      controls. To address these hypotheses, we will recruit three groups of participants: Patients&#xD;
      with AD, their spousal caregivers, and controls that are age-matched with the caregivers.&#xD;
      Their gut microbiome and indices of neuroinflammation and neuropathology in the blood will be&#xD;
      determined. Their cognition will be assessed. The correction of cognition with gut microbiome&#xD;
      genera or indices in the blood will be analyzed. Our studies may represent the first study to&#xD;
      determine whether the gut microbiome and SCFAs may play a role in the cognitive impairment in&#xD;
      the spousal caregivers of patients with AD. These studies may also identify biomarkers for&#xD;
      cognitive impairment in these caregivers and patients with AD. These findings may ultimately&#xD;
      help the care of patients with AD and reduce the cognitive declines in spousal caregivers of&#xD;
      patients with AD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2022</start_date>
  <completion_date type="Anticipated">November 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Inflammation related biomarkers</measure>
    <time_frame>one day</time_frame>
    <description>interleukin (IL)-1β, IL-6, IL-10, IL-17, complement 3 (C3,) and YKL-40</description>
  </primary_outcome>
  <primary_outcome>
    <measure>amyloid biomarker</measure>
    <time_frame>one day</time_frame>
    <description>amyloid beta (Aβ)1-42</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ratio of Aβ1-42 and Aβ1-40</measure>
    <time_frame>one day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>total tau biomarker</measure>
    <time_frame>one day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>phospho-tau at 181 or 217 biomarker</measure>
    <time_frame>one day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>neurodegeneration related biomarkers</measure>
    <time_frame>one day</time_frame>
    <description>neurofilament light chain (NFL) and neurogranin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>serum short chain fatty acids</measure>
    <time_frame>one day</time_frame>
    <description>acetic acid, propionic acid, isobutyric acid, butyric acid, valeric acid and hexanic acid</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Gut Biome</condition>
  <arm_group>
    <arm_group_label>Alzheimer's Patient</arm_group_label>
    <description>patients with AD whose clinical dementia rating (CDR) is &gt; 1 Age 65-90 with none of the criteria below:&#xD;
Familial Alzheimer's Disease (AD)&#xD;
Severe cardiovascular disease&#xD;
Severe respiratory system disease&#xD;
Severe liver disease&#xD;
Severe kidney disease&#xD;
Severe central nervous system diseases&#xD;
Having a lifespan of fewer than 3 months&#xD;
History of psychiatric illness&#xD;
Major neurological diseases other than AD&#xD;
Current use of corticosteroids, antibiotics, or bowel motility modification agents&#xD;
Any history of Alcoholism or illicit drug dependence&#xD;
Previous inclusion in this study&#xD;
Difficulty with follow-up or poor compliance&#xD;
Severe hearing impairment&#xD;
Severe vision impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Spousal Caregiver to Alzheimer's Patient</arm_group_label>
    <description>Spousal Caregiver to &quot;Alzheimer's Patient&quot; group, Age 65-90 with none of the criteria below:&#xD;
Familial Alzheimer's Disease (AD)&#xD;
Severe cardiovascular disease&#xD;
Severe respiratory system disease&#xD;
Severe liver disease&#xD;
Severe kidney disease&#xD;
Severe central nervous system diseases&#xD;
Having a lifespan of fewer than 3 months&#xD;
History of psychiatric illness&#xD;
Major neurological diseases other than AD&#xD;
Current use of corticosteroids, antibiotics, or bowel motility modification agents&#xD;
Any history of Alcoholism or illicit drug dependence&#xD;
Previous inclusion in this study&#xD;
Difficulty with follow-up or poor compliance&#xD;
Severe hearing impairment&#xD;
Severe vision impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy adult control</arm_group_label>
    <description>Age-matched to &quot;Spousal Caregiver to Alzheimer's Patient&quot; group Age 65-90 with none of the criteria below:&#xD;
Familial Alzheimer's Disease (AD)&#xD;
Severe cardiovascular disease&#xD;
Severe respiratory system disease&#xD;
Severe liver disease&#xD;
Severe kidney disease&#xD;
Severe central nervous system diseases&#xD;
Having a lifespan of fewer than 3 months&#xD;
History of psychiatric illness&#xD;
Major neurological diseases other than AD&#xD;
Current use of corticosteroids, antibiotics, or bowel motility modification agents&#xD;
Any history of Alcoholism or illicit drug dependence&#xD;
Previous inclusion in this study&#xD;
Difficulty with follow-up or poor compliance&#xD;
Severe hearing impairment&#xD;
Severe vision impairment</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood Serum, 5 mL Stool Samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adults who are at risk for Alzheimer's Disease.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. patients with AD whose clinical dementia rating (CDR) is &gt; 1&#xD;
&#xD;
          2. Spouses of Patients in the above group Or&#xD;
&#xD;
          3. Healthy adult unrelated to groups 1 and 2, with no history of dementia And&#xD;
&#xD;
          4. Regardless of the grouping, the prospective subject must be between 65 and 90 years&#xD;
             old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Familial Alzheimer's Disease (AD)&#xD;
&#xD;
          2. Severe cardiovascular disease&#xD;
&#xD;
          3. Severe respiratory system disease&#xD;
&#xD;
          4. Severe liver disease&#xD;
&#xD;
          5. Severe kidney disease&#xD;
&#xD;
          6. Severe central nervous system diseases&#xD;
&#xD;
          7. Having a lifespan of fewer than 3 months&#xD;
&#xD;
          8. History of psychiatric illness&#xD;
&#xD;
          9. Major neurological diseases other than AD&#xD;
&#xD;
         10. Current use of corticosteroids, antibiotics, or bowel motility modification agents&#xD;
&#xD;
         11. Any history of Alcoholism or illicit drug dependence&#xD;
&#xD;
         12. Previous inclusion in this study&#xD;
&#xD;
         13. Difficulty with follow-up or poor compliance&#xD;
&#xD;
         14. Severe hearing impairment&#xD;
&#xD;
         15. Severe vision impairment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Keita Ikeda, PHD</last_name>
    <phone>9195931174</phone>
    <email>keita.ikeda@virginia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>ZHIYI ZUO, MD PHD</last_name>
    <phone>4349824481</phone>
    <email>zz3c@uvahealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908-0710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Vassar R, Citron M. Abeta-generating enzymes: recent advances in beta- and gamma-secretase research. Neuron. 2000 Sep;27(3):419-22. Review.</citation>
    <PMID>11055423</PMID>
  </reference>
  <reference>
    <citation>Vassar R. BACE1: the beta-secretase enzyme in Alzheimer's disease. J Mol Neurosci. 2004;23(1-2):105-14. Review.</citation>
    <PMID>15126696</PMID>
  </reference>
  <reference>
    <citation>Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001 Apr;81(2):741-66. Review.</citation>
    <PMID>11274343</PMID>
  </reference>
  <reference>
    <citation>Wang WY, Tan MS, Yu JT, Tan L. Role of pro-inflammatory cytokines released from microglia in Alzheimer's disease. Ann Transl Med. 2015 Jun;3(10):136. doi: 10.3978/j.issn.2305-5839.2015.03.49. Review.</citation>
    <PMID>26207229</PMID>
  </reference>
  <reference>
    <citation>Saji N, Murotani K, Hisada T, Tsuduki T, Sugimoto T, Kimura A, Niida S, Toba K, Sakurai T. The relationship between the gut microbiome and mild cognitive impairment in patients without dementia: a cross-sectional study conducted in Japan. Sci Rep. 2019 Dec 18;9(1):19227. doi: 10.1038/s41598-019-55851-y.</citation>
    <PMID>31852995</PMID>
  </reference>
  <reference>
    <citation>Guo M, Peng J, Huang X, Xiao L, Huang F, Zuo Z. Gut Microbiome Features of Chinese Patients Newly Diagnosed with Alzheimer's Disease or Mild Cognitive Impairment. J Alzheimers Dis. 2021;80(1):299-310. doi: 10.3233/JAD-201040.</citation>
    <PMID>33523001</PMID>
  </reference>
  <reference>
    <citation>Wang X, Sun G, Feng T, Zhang J, Huang X, Wang T, Xie Z, Chu X, Yang J, Wang H, Chang S, Gong Y, Ruan L, Zhang G, Yan S, Lian W, Du C, Yang D, Zhang Q, Lin F, Liu J, Zhang H, Ge C, Xiao S, Ding J, Geng M. Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer's disease progression. Cell Res. 2019 Oct;29(10):787-803. doi: 10.1038/s41422-019-0216-x. Epub 2019 Sep 6.</citation>
    <PMID>31488882</PMID>
  </reference>
  <reference>
    <citation>Kim MS, Kim Y, Choi H, Kim W, Park S, Lee D, Kim DK, Kim HJ, Choi H, Hyun DW, Lee JY, Choi EY, Lee DS, Bae JW, Mook-Jung I. Transfer of a healthy microbiota reduces amyloid and tau pathology in an Alzheimer's disease animal model. Gut. 2020 Feb;69(2):283-294. doi: 10.1136/gutjnl-2018-317431. Epub 2019 Aug 30.</citation>
    <PMID>31471351</PMID>
  </reference>
  <reference>
    <citation>Li B, He Y, Ma J, Huang P, Du J, Cao L, Wang Y, Xiao Q, Tang H, Chen S. Mild cognitive impairment has similar alterations as Alzheimer's disease in gut microbiota. Alzheimers Dement. 2019 Oct;15(10):1357-1366. doi: 10.1016/j.jalz.2019.07.002. Epub 2019 Aug 18.</citation>
    <PMID>31434623</PMID>
  </reference>
  <reference>
    <citation>Lai Z, Shan W, Li J, Min J, Zeng X, Zuo Z. Appropriate exercise level attenuates gut dysbiosis and valeric acid increase to improve neuroplasticity and cognitive function after surgery in mice. Mol Psychiatry. 2021 Dec;26(12):7167-7187. doi: 10.1038/s41380-021-01291-y. Epub 2021 Oct 18.</citation>
    <PMID>34663905</PMID>
  </reference>
  <reference>
    <citation>Liu H, McPherson BC, Zhu X, Da Costa ML, Jeevanandam V, Yao Z. Role of nitric oxide and protein kinase C in ACh-induced cardioprotection. Am J Physiol Heart Circ Physiol. 2001 Jul;281(1):H191-7.</citation>
    <PMID>11406485</PMID>
  </reference>
  <reference>
    <citation>Colombo AV, Sadler RK, Llovera G, Singh V, Roth S, Heindl S, Sebastian Monasor L, Verhoeven A, Peters F, Parhizkar S, Kamp F, Gomez de Aguero M, MacPherson AJ, Winkler E, Herms J, Benakis C, Dichgans M, Steiner H, Giera M, Haass C, Tahirovic S, Liesz A. Microbiota-derived short chain fatty acids modulate microglia and promote Aβ plaque deposition. Elife. 2021 Apr 13;10. pii: e59826. doi: 10.7554/eLife.59826.</citation>
    <PMID>33845942</PMID>
  </reference>
  <reference>
    <citation>Marizzoni M, Cattaneo A, Mirabelli P, Festari C, Lopizzo N, Nicolosi V, Mombelli E, Mazzelli M, Luongo D, Naviglio D, Coppola L, Salvatore M, Frisoni GB. Short-Chain Fatty Acids and Lipopolysaccharide as Mediators Between Gut Dysbiosis and Amyloid Pathology in Alzheimer's Disease. J Alzheimers Dis. 2020;78(2):683-697. doi: 10.3233/JAD-200306.</citation>
    <PMID>33074224</PMID>
  </reference>
  <reference>
    <citation>Norton MC, Smith KR, Østbye T, Tschanz JT, Corcoran C, Schwartz S, Piercy KW, Rabins PV, Steffens DC, Skoog I, Breitner JC, Welsh-Bohmer KA; Cache County Investigators. Greater risk of dementia when spouse has dementia? The Cache County study. J Am Geriatr Soc. 2010 May;58(5):895-900. doi: 10.1111/j.1532-5415.2010.02806.x. Erratum in: J Am Geriatr Soc. 2012 May;60(5):1000. J Am Geriatr Soc. 2013 Sep;61(9):1642.</citation>
    <PMID>20722820</PMID>
  </reference>
  <reference>
    <citation>Vitaliano PP, Zhang J, Scanlan JM. Is caregiving hazardous to one's physical health? A meta-analysis. Psychol Bull. 2003 Nov;129(6):946-72.</citation>
    <PMID>14599289</PMID>
  </reference>
  <reference>
    <citation>Drouet B, Pinçon-Raymond M, Chambaz J, Pillot T. Molecular basis of Alzheimer's disease. Cell Mol Life Sci. 2000 May;57(5):705-15. Review.</citation>
    <PMID>10892337</PMID>
  </reference>
  <reference>
    <citation>Götz J, Streffer JR, David D, Schild A, Hoerndli F, Pennanen L, Kurosinski P, Chen F. Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy. Mol Psychiatry. 2004 Jul;9(7):664-83. Review.</citation>
    <PMID>15052274</PMID>
  </reference>
  <reference>
    <citation>Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci. 2015 Jun;16(6):358-72. doi: 10.1038/nrn3880. Review.</citation>
    <PMID>25991443</PMID>
  </reference>
  <reference>
    <citation>Dassel KB, Carr DC, Vitaliano P. Does Caring for a Spouse With Dementia Accelerate Cognitive Decline? Findings From the Health and Retirement Study. Gerontologist. 2017 Apr 1;57(2):319-328. doi: 10.1093/geront/gnv148.</citation>
    <PMID>26582383</PMID>
  </reference>
  <reference>
    <citation>Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, Hampel H, Jagust WJ, Johnson KA, Knopman DS, Petersen RC, Scheltens P, Sperling RA, Dubois B. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016 Aug 2;87(5):539-47. doi: 10.1212/WNL.0000000000002923. Epub 2016 Jul 1. Review.</citation>
    <PMID>27371494</PMID>
  </reference>
  <reference>
    <citation>Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Snyder HM, Sperling R; Contributors. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018 Apr;14(4):535-562. doi: 10.1016/j.jalz.2018.02.018. Review.</citation>
    <PMID>29653606</PMID>
  </reference>
  <reference>
    <citation>Blennow K, Zetterberg H. Biomarkers for Alzheimer's disease: current status and prospects for the future. J Intern Med. 2018 Dec;284(6):643-663. doi: 10.1111/joim.12816. Epub 2018 Aug 19. Review.</citation>
    <PMID>30051512</PMID>
  </reference>
  <reference>
    <citation>Hellwig K, Kvartsberg H, Portelius E, Andreasson U, Oberstein TJ, Lewczuk P, Blennow K, Kornhuber J, Maler JM, Zetterberg H, Spitzer P. Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease. Alzheimers Res Ther. 2015 Dec 24;7:74. doi: 10.1186/s13195-015-0161-y.</citation>
    <PMID>26698298</PMID>
  </reference>
  <reference>
    <citation>Sharma N, Singh AN. Exploring Biomarkers for Alzheimer's Disease. J Clin Diagn Res. 2016 Jul;10(7):KE01-6. doi: 10.7860/JCDR/2016/18828.8166. Epub 2016 Jul 1. Review.</citation>
    <PMID>27630867</PMID>
  </reference>
  <reference>
    <citation>Minter MR, Zhang C, Leone V, Ringus DL, Zhang X, Oyler-Castrillo P, Musch MW, Liao F, Ward JF, Holtzman DM, Chang EB, Tanzi RE, Sisodia SS. Antibiotic-induced perturbations in gut microbial diversity influences neuro-inflammation and amyloidosis in a murine model of Alzheimer's disease. Sci Rep. 2016 Jul 21;6:30028. doi: 10.1038/srep30028.</citation>
    <PMID>27443609</PMID>
  </reference>
  <reference>
    <citation>Bonfili L, Cecarini V, Berardi S, Scarpona S, Suchodolski JS, Nasuti C, Fiorini D, Boarelli MC, Rossi G, Eleuteri AM. Microbiota modulation counteracts Alzheimer's disease progression influencing neuronal proteolysis and gut hormones plasma levels. Sci Rep. 2017 May 25;7(1):2426. doi: 10.1038/s41598-017-02587-2.</citation>
    <PMID>28546539</PMID>
  </reference>
  <reference>
    <citation>Harach T, Marungruang N, Duthilleul N, Cheatham V, Mc Coy KD, Frisoni G, Neher JJ, Fåk F, Jucker M, Lasser T, Bolmont T. Reduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota. Sci Rep. 2017 Feb 8;7:41802. doi: 10.1038/srep41802. Erratum in: Sci Rep. 2017 Jul 10;7:46856.</citation>
    <PMID>28176819</PMID>
  </reference>
  <reference>
    <citation>Biagi E, Nylund L, Candela M, Ostan R, Bucci L, Pini E, Nikkïla J, Monti D, Satokari R, Franceschi C, Brigidi P, De Vos W. Through ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians. PLoS One. 2010 May 17;5(5):e10667. doi: 10.1371/journal.pone.0010667. Erratum in: PLoS One. 2010;5(6). doi: 10.1371/annotation/df45912f-d15c-44ab-8312-e7ec0607604d.</citation>
    <PMID>20498852</PMID>
  </reference>
  <reference>
    <citation>Chen H, Meng L, Shen L. Multiple roles of short-chain fatty acids in Alzheimer disease. Nutrition. 2022 Jan;93:111499. doi: 10.1016/j.nut.2021.111499. Epub 2021 Sep 23. Review.</citation>
    <PMID>34735921</PMID>
  </reference>
  <reference>
    <citation>Liu J, Li H, Gong T, Chen W, Mao S, Kong Y, Yu J, Sun J. Anti-neuroinflammatory Effect of Short-Chain Fatty Acid Acetate against Alzheimer's Disease via Upregulating GPR41 and Inhibiting ERK/JNK/NF-κB. J Agric Food Chem. 2020 Jul 8;68(27):7152-7161. doi: 10.1021/acs.jafc.0c02807. Epub 2020 Jun 25.</citation>
    <PMID>32583667</PMID>
  </reference>
  <reference>
    <citation>Killingsworth J, Sawmiller D, Shytle RD. Propionate and Alzheimer's Disease. Front Aging Neurosci. 2021 Jan 11;12:580001. doi: 10.3389/fnagi.2020.580001. eCollection 2020. Review.</citation>
    <PMID>33505301</PMID>
  </reference>
  <reference>
    <citation>McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 May;7(3):263-9. doi: 10.1016/j.jalz.2011.03.005. Epub 2011 Apr 21.</citation>
    <PMID>21514250</PMID>
  </reference>
  <reference>
    <citation>Sherwin E, Dinan TG, Cryan JF. Recent developments in understanding the role of the gut microbiota in brain health and disease. Ann N Y Acad Sci. 2018 May;1420(1):5-25. doi: 10.1111/nyas.13416. Epub 2017 Aug 2. Review.</citation>
    <PMID>28768369</PMID>
  </reference>
  <reference>
    <citation>Olsson B, Lautner R, Andreasson U, Öhrfelt A, Portelius E, Bjerke M, Hölttä M, Rosén C, Olsson C, Strobel G, Wu E, Dakin K, Petzold M, Blennow K, Zetterberg H. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol. 2016 Jun;15(7):673-684. doi: 10.1016/S1474-4422(16)00070-3. Epub 2016 Apr 8. Review.</citation>
    <PMID>27068280</PMID>
  </reference>
  <reference>
    <citation>Cao L, Li L, Lin D, Zuo Z. Isoflurane induces learning impairment that is mediated by interleukin 1β in rodents. PLoS One. 2012;7(12):e51431. doi: 10.1371/journal.pone.0051431. Epub 2012 Dec 12.</citation>
    <PMID>23251531</PMID>
  </reference>
  <reference>
    <citation>Wang Z, Meng S, Cao L, Chen Y, Zuo Z, Peng S. Critical role of NLRP3-caspase-1 pathway in age-dependent isoflurane-induced microglial inflammatory response and cognitive impairment. J Neuroinflammation. 2018 Apr 17;15(1):109. doi: 10.1186/s12974-018-1137-1.</citation>
    <PMID>29665808</PMID>
  </reference>
  <reference>
    <citation>Zhang J, Tan H, Jiang W, Zuo Z. Amantadine alleviates postoperative cognitive dysfunction possibly by increasing glial cell line-derived neurotrophic factor in rats. Anesthesiology. 2014 Oct;121(4):773-85. doi: 10.1097/ALN.0000000000000352.</citation>
    <PMID>25251457</PMID>
  </reference>
  <reference>
    <citation>Li H, Yin J, Li L, Deng J, Feng C, Zuo Z. Isoflurane postconditioning reduces ischemia-induced nuclear factor-κB activation and interleukin 1β production to provide neuroprotection in rats and mice. Neurobiol Dis. 2013 Jun;54:216-24. doi: 10.1016/j.nbd.2012.12.014. Epub 2013 Jan 8.</citation>
    <PMID>23313315</PMID>
  </reference>
  <reference>
    <citation>Li J, Sheng W, Feng C, Zuo Z. Pyrrolidine dithiocarbamate attenuates brain Aβ increase and improves long-term neurological outcome in rats after transient focal brain ischemia. Neurobiol Dis. 2012 Jan;45(1):564-72. doi: 10.1016/j.nbd.2011.09.013. Epub 2011 Sep 24.</citation>
    <PMID>21983158</PMID>
  </reference>
  <reference>
    <citation>Watt G, Shang K, Zieba J, Olaya J, Li H, Garner B, Karl T. Chronic Treatment with 50 mg/kg Cannabidiol Improves Cognition and Moderately Reduces Aβ40 Levels in 12-Month-Old Male AβPPswe/PS1ΔE9 Transgenic Mice. J Alzheimers Dis. 2020;74(3):937-950. doi: 10.3233/JAD-191242.</citation>
    <PMID>32116258</PMID>
  </reference>
  <reference>
    <citation>Randolph C, Tierney MC, Mohr E, Chase TN. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol. 1998 Jun;20(3):310-9.</citation>
    <PMID>9845158</PMID>
  </reference>
  <reference>
    <citation>Li Y, Chen D, Wang H, Wang Z, Song F, Li H, Ling L, Shen Z, Hu C, Peng J, Li W, Xing W, Pan J, Liang H, Zhou Q, Cai J, He Z, Peng S, Zeng W, Zuo Z. Intravenous versus Volatile Anesthetic Effects on Postoperative Cognition in Elderly Patients Undergoing Laparoscopic Abdominal Surgery. Anesthesiology. 2021 Mar 1;134(3):381-394. doi: 10.1097/ALN.0000000000003680.</citation>
    <PMID>33439974</PMID>
  </reference>
  <verification_date>October 2022</verification_date>
  <study_first_submitted>October 27, 2022</study_first_submitted>
  <study_first_submitted_qc>October 31, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2022</study_first_posted>
  <last_update_submitted>October 31, 2022</last_update_submitted>
  <last_update_submitted_qc>October 31, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Zhiyi Zuo, MD</investigator_full_name>
    <investigator_title>Professor, Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>Alzheimers</keyword>
  <keyword>biome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>If shared, it will be de-identified data.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

